Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells

• Published in: Breast cancer research : BCR Vol. 7; no. 5; pp. R765 - R774
• Main Authors: Rehman, Abdur, Chahal, Manpreet S, Tang, Xiaoting, Bruce, James E, Pommier, Yves, Daoud, Sayed S
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.01.2005; National Library of Medicine - MEDLINE Abstracts; BioMed Central
• Subjects: Amino Acid Substitution; Analysis; Anthracyclines; Antibodies; Apoptosis; Aza Compounds - metabolism; Aza Compounds - therapeutic use; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Bridged Bicyclo Compounds, Heterocyclic - metabolism; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Cancer; Cancer cells; Care and treatment; Cell Line, Tumor; Doxorubicin - pharmacology; Female; Genetic aspects; Genetic research; Genetic transcription; Health aspects; Heat shock proteins; HSP90 Heat-Shock Proteins - genetics; HSP90 Heat-Shock Proteins - metabolism; Humans; Immunohistochemistry; Ionization; Mutagenesis, Site-Directed; Mutation; Protein binding; Proteome; Tumor proteins; Tumor Suppressor Protein p53 - genetics; Viral antibodies
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/bcr1290

A loss of p53 function resulting from mutation is prevalent in human cancers. Thus, restoration of p53 function to mutant p53 using small compounds has been extensively studied for cancer therapy. We previously reported that PRIMA-1 (for 'p53 reactivation and induction of massive apoptosis') restored the transcriptional activity of p53 target genes in breast cancer cells with a p53 mutation. By using functional proteomics approach, we sought to identify molecular targets that are involved in the restoration of normal function to mutant p53. PRIMA-1 treated cell lysates were subjected to immunoprecipitation with DO-1 primary antibody against p53 protein, and proteins bound to p53 were separated on a denaturing gel. Bands expressed differentially between control and PRIMA-1-treated cells were then identified by matrix-assisted laser desorption ionization-time-of-flight spectrometry. Protein expression in whole cell lysates and nuclear extracts were confirmed by Western blotting. The effect of combined treatment of PRIMA-1 and adriamycin in breast cancer cells was determined with a cytotoxicity assay in vitro. PRIMA-1 treated cells distinctly expressed a protein band of 90 kDa that was identified as heat shock protein 90 (Hsp90) by the analysis of the 90 kDa band tryptic digest. Immunoblotting with isoform-specific antibodies against Hsp90 identified this band as the alpha isoform of Hsp90 (Hsp90alpha). Co-immunoprecipitation with anti-Hsp90alpha antibody followed by immunoblotting with DO-1 confirmed that p53 and Hsp90alpha were interacting proteins. PRIMA-1 treatment also resulted in the translocation of Hsp90alpha to the nucleus by 8 hours. Treatment of cells with PRIMA-1 alone or in combination with adriamycin, a DNA-targeted agent, resulted in increased sensitivity of tumor cells. The studies demonstrate that PRIMA-1 restores the p53-Hsp90alpha interaction, enhances the translocation of the p53-Hsp90alpha complex and reactivates p53 transcriptional activity. Our preliminary evidence also suggests that PRIMA-1 could be considered in combination therapy with DNA-targeted agents for the treatment of breast cancer, especially for tumors with aberrant p53 function.